Top

Journal of Cancer Research and Clinical Oncology

Published in:

09-04-2023 | Metastasis | Research

Prognostic effect of CD73 in pancreatic ductal adenocarcinoma for disease-free survival after radical surgery

Authors: Dailei Qin, Ran Wei, Kewei Huang, Ruiqi Wang, Honglu Ding, Zehui Yao, Pu Xi, Shengping Li

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2023

Abstract

Purpose

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a high potency of metastasis or recurrence after radical resection. Effective predictors for metastasis and recurrence postoperatively were dominant for the development of systemic adjuvant treatment regimens. The ATP hydrolase correlated gene CD73 was described as a promoter in tumor growth and immune escape of PDAC. However, there lacked research focused on the role of CD73 in PDAC metastasis. This study aimed to investigate the expression of CD73 in PDAC patients with different outcomes as well as the prognostic effect of CD73 for disease-free survival (DFS).

Methods

The expression level of CD73 in cancerous samples from 301 PDAC patients was evaluated by immunohistochemistry (IHC) and translated into a histochemistry score (H-score) by the HALO analysis system. Then, the CD73 H-score was involved in multivariate Cox regression along with other clinicopathological characteristics to find independent prognostic factors for DFS. Finally, a nomogram was constructed based on those independent prognostic factors for DFS prediction.

Results

Higher CD73 expression was found in PDAC patients with tumor metastasis postoperatively. Meanwhile, higher CD73 expressions were also investigated in PDAC patients diagnosed with advanced N stage and T stage. Furthermore, CD73 H-score along with tumor margin status, CA19-9, 8th N stage, and adjuvant chemotherapy was indicated as independent prognostic factors for DFS in PDAC patients. The nomogram based on these factors predicted DFS in a good manner.

Conclusion

CD73 was associated with PDAC metastasis and served as an effective prognostic factor for DFS in PDAC patients after radical surgery.

Aeffner F, Wilson K, Martin NT, Black JC, Hendriks CL, Bolon B, Rudmann DG, Gianani R, Koegler SR, Krueger J, Young GD (2017) The gold standard paradox in digital image analysis: manual versus automated scoring as ground truth. Arch Pathol Lab Med 141:1267–1275PubMed

Azambuja JH, Gelsleichter NE, Beckenkamp LR, Iser IC, Fernandes MC, Figueiró F, Battastini AM, Scholl JN, de Oliveira FH, Spanevello RM, Sévigny J (2019) CD73 downregulation decreases in vitro and in vivo glioblastoma growth. Mol Neurobiol 56:3260–3279PubMed

Bednar F, di Magliano P (2020) Chemotherapy and tumor evolution shape pancreatic cancer recurrence after resection. Cancer Discov 10:762–764PubMed

Chang DK, Johns AL, Merrett ND, Gill AJ, Colvin EK, Scarlett CJ, Nguyen NQ, Leong RW, Cosman PH, Kelly MI, Sutherland RL, Henshall SM, Kench JG, Biankin AV (2009) Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 27:2855–62PubMed

Driscoll JJ, Rixe O (2009) Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials. Cancer J 15:401–5PubMed

Ellison LF, Wilkins K (2010) An update on cancer survival. Health Rep 21:55–60PubMed

Gebauer F, Tachezy M, Vashist YK, Marx AH, Yekebas E, Izbicki JR, Bockhorn M (2015) Resection margin clearance in pancreatic cancer after implementation of the Leeds Pathology Protocol (LEEPP): clinically relevant or just academic? World J Surg 39:493–9PubMed

Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, Weiss MJ, Zheng L, Wolfgang CL, He J (2018) Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg 267:936–945PubMed

Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA, Burkhart RA, Rinkes IH, Molenaar IQ, Cameron JL, Weiss MJ, Wolfga CL, He J (2019) Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg 269:1154–1162PubMed

Hainaut P, Plymoth A (2013) Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol 25:50–51PubMed

Huangi S, Apasov S, Koshiba M, Sitkovsky M (1997) Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 90:1600–1610

Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G, Klein CA (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13:58–68PubMed

Inoue Y, Yoshimura K, Kurabe N, Kahyo T, Kawase A, Tanahashi M, Ogawa H, Inui N, Funai K, Shinmura K, Niwa H (2017) Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. Oncotarget 8:8738–8751PubMedPubMedCentral

Kawada K, Taketo MT (2011) Significance and mechanism of lymph node metastasis in cancer progression. Can Res 71:1214–1218

Lutty GA, Mathews MK, Merges C, MCleod DS (1998) Adenosine stimulates canine retinal microvascular endothelial cell migration and tube formation. Curr Eye Res 17:594–607PubMed

Ma XL, Shen MN, Hu B, Wang BL, Yang WJ, Lv LH, Wang H, Zhou Y, Jin AL, Sun YF, Zhang CY (2019) CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis. J Hematol Oncol 12:37PubMedPubMedCentral

Malleo G, Maggino L, Capelli P, Gulino F, Segattini S, Scarpa A, Bassi C, Butturini G, Salvia R (2015) Reappraisal of nodal staging and study of lymph node station involvement in pancreaticoduodenectomy with the standard international study group of pancreatic surgery definition of lymphadenectomy for cancer. J Am Coll Surg 221:367–79.e4PubMed

Mathoulin-Pelissier S, Gourgou-Bourgade S, Bonnetain F, Kramar A (2008) Survival end point reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol 26:3721–6PubMed

Messaoudi N, Cousineau I, Arslanian E, Henault D, Stephen D, Vandenbroucke-Menu F, Dagenais M, Létourneau R, Plasse M, Roy A, Lapointe R (2020) Prognostic value of CD73 expression in resected colorectal cancer liver metastasis. Oncoimmunology 9:1746138PubMedPubMedCentral

Meyerholz DK, Beck AP (2018) Principles and approaches for reproducible scoring of tissue stains in research. Lab Investig 98:844–855PubMed

Morrison LE, Lefever MR, Behman LJ, Leibold T, Roberts EA, Horchner UB, Bauer DR (2020) Brightfield multiplex immunohistochemistry with multispectral imaging. Lab Investig 100:1124–1136PubMed

Occhionorelli S, Andreotti D, Vallese P, Morganti L, Lacavalla D, Forini E, Pascale G (2018) Evaluation on prognostic efficacy of lymph nodes ratio (LNR) and log odds of positive lymph nodes (LODDS) in complicated colon cancer: the first study in emergency surgery. World J Surg Oncol 16:186PubMedPubMedCentral

Paiella S, Sandini M, Gianotti L, Butturini G, Salvia R, Bassi C (2016) The prognostic impact of para-aortic lymph node metastasis in pancreatic cancer: a systematic review and meta-analysis. Eur J Surg Oncol 42:616–24PubMed

Prassas D, Safi SA, Stylianidi MC, Telan LA, Krieg S, Roderburg C, Esposito I, Luedde T, Knoefel WT, Krieg A (2022) N, LNR or LODDS: which is the most appropriate lymph node classification scheme for patients with radically resected pancreatic cancer? Cancers 14:1834PubMedPubMedCentral

Rathbone MP, Middlemiss PJ, Kim JK, Gysbers JW, DeForge SP, Smith RW, Hughes DW (1992) Adenosine and its nucleotides stimulate proliferation of chick astrocytes and human astrocytoma cells. Neurosci Res 13:1–17PubMed

Rawla P, Sunkara T, Gaduputi V (2019) Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol 10:10–27PubMedPubMedCentral

Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD (2012) EMT and dissemination precede pancreatic tumor formation. Cell 148:349–61PubMedPubMedCentral

Robinson AG, Booth CM, Eisenhauer EA (2014) Disease-free survival as an end-point in the treatment of solid tumours–perspectives from clinical trials and clinical practice. Eur J Cancer 50:2298–302PubMed

Robinson AG, Booth CM, Eisenhauer EA (2014) Progression-free survival as an end-point in solid tumours–perspectives from clinical trials and clinical practice. Eur J Cancer 50:2303–8PubMed

Schito L, Semenza GL (2016) Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer 2:758–770PubMed

Semenza GL (2016) The hypoxic tumor microenvironment: A driving force for breast cancer progression. Biochem Biophys Acta 1863:382–391PubMed

Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30PubMed

Suenaga M, Fujii T, Kanda M, Takami H, Okumura N, Inokawa Y, Kobayashi D, Tanaka C, Yamada S, Sugimoto H, Nomoto S (2014) Pattern of first recurrent lesions in pancreatic cancer: hepatic relapse is associated with dismal prognosis and portal vein invasion. Hepato-Gastroenterology 61:1756–61PubMed

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249PubMed

Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, Hansen KR, Thompson LF, Colgan SP (2002) Ecto-5’-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. The J Clin Investig 110:993–1002PubMed

Tahkola K, Ahtiainen M, Kellokumpu I, Mecklin JP, Laukkarinen J, Laakkonen J, Kenessey I, Jalkanen S, Salmi M, Böhm J (2021) Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer. Virchows Arch 478:209–217PubMed

Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M (2021) Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 19:439–457

Toki MI, Merritt CR, Wong PF, Smithy JW, Kluger HM, Syrigos KN, Ong GT, Warren SE, Beechem JM, Rimm DL (2019) High-plex predictive marker discovery for melanoma immunotherapy-treated patients using digital spatial profiling. Clin Cancer Res 25:5503–5512PubMedPubMedCentral

Tripathi A, Lin E, Xie W et al (2020) Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. J Immunother Cancer 8:e001467. https://doi.org/10.1136/jitc-2020-001467

Trivedi MS, Hoffner B, Winkelmann JL, Abbott ME, Hamid O, Carvajal, (2015) Programmed death 1 immune checkpoint inhibitors. Clin Adv Hematol Oncol 13:858–68PubMed

Valsangkar NP, Bush DM, Michaelson JS, Ferrone CR, Wargo JA, Lillemoe KD, Fernández-del Castillo C, Warshaw AL, Thayer SP (2013) N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. J Gastrointest Surg 17:257–66PubMed

Verbeke CS, Gladhaug IP (2012) Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg 99:1036–1049PubMed

Viratham Pulsawatdi A, Craig SG, Bingham V, McCombe K, Humphries MP, Senevirathne S, Richman SD, Quirke P, Campo L, Domingo E, Maughan TS (2020) A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment. Mol Oncol 14:2384–2402PubMedPubMedCentral

Xu Z, Gu C, Yao X, Guo W, Wang H, Lin T, Li F, Chen D, Wu J, Ye G, Zhao L (2020) CD73 promotes tumor metastasis by modulating RICS/RhoA signaling and EMT in gastric cancer. Cell Death Dis 11:202PubMedPubMedCentral

Yu J, Wang X, Lu Q, Wang J, Li L, Liao X, Zhu W, Lv L, Zhi X, Yu J, Jin Y (2018) Extracellular 5’-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3β/β-catenin/cyclinD1 signaling pathway. Int J Cancer 142:959–967PubMed

Zhang B (2012) CD73 promotes tumor growth and metastasis. Oncoimmunology 1:67–70PubMedPubMedCentral

Zhang H, Cao Y, Tang J, Wang R (2022) CD73 (NT5E) promotes the proliferation and metastasis of lung adenocarcinoma through the EGFR/AKT/mTOR pathway. BioMed Res Int 2022:9944847PubMedPubMedCentral

Title: Prognostic effect of CD73 in pancreatic ductal adenocarcinoma for disease-free survival after radical surgery
Authors: Dailei Qin
Ran Wei
Kewei Huang
Ruiqi Wang
Honglu Ding
Zehui Yao
Pu Xi
Shengping Li
Publication date: 09-04-2023
Publisher: Springer Berlin Heidelberg
Keyword: Metastasis
Published in: Journal of Cancer Research and Clinical Oncology / Issue 10/2023
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-023-04703-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2023

The evaluation of tumor microenvironment infiltration and the identification of angiogenesis-related subgroups in skin cutaneous melanoma

Molecular markers predicting the progression and prognosis of human papillomavirus-induced cervical lesions to cervical cancer

Dissecting the inflammatory tumor microenvironment of esophageal adenocarcinoma: mast cells and natural killer cells are favorable prognostic factors and associated with less extensive disease

Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany

Two decades of gastric and gastroesophageal junction cancer surgery

Based on ARASENS trial: efficacy and safety of darolutamide as an emerging option of endocrinotherapy for metastatic hormone-sensitive prostate cancer—an updated systematic review and network meta-analysis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials